Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points PCCs for the management of major bleeding in patients on rivaroxaban or apixaban is an effective strategy in most cases. The thromboembolic complication rate in this setting is low and comparable with that of anticoagulation discontinuation without reversal.

authors

Majeed, Ammar
Ågren, Anna
Holmström, Margareta
Bruzelius, Maria
Chaireti, Roza
Odeberg, Jacob
Hempel, Eva-Lotta
Magnusson, Maria
Frisk, Tony
Schulman, Sam

status

published

publication date

October 12, 2017

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Aged (MeSH)
Aged, 80 and over (MeSH)
Blood Coagulation Factors (MeSH)
Cohort Studies (MeSH)
Demography (MeSH)
Female (MeSH)
Hemorrhage (MeSH)
Humans (MeSH)
Immunology (Science Metrix)
Male (MeSH)
Pyrazoles (MeSH)
Pyridones (MeSH)
Rivaroxaban (MeSH)
Thromboembolism (MeSH)
Treatment Outcome (MeSH)

published in

Blood Journal